50% enrollment milestone reached in Diamyd Medical’s European Phase II trial

Half of the patients, 40 out of 80, are now included in the European Phase II trial DIAGNODE-2, where the diabetes vaccine Diamyd® is administered directly into the lymph node.“We are very pleased with the great interest in DIAGNODE-2, and the great commitment from the 18 leading clinics in Spain, the Czech Republic and Sweden where the trial is conducted, which enables the efficient recruitment of trial participants,” says Ulf Hannelius, CEO of Diamyd Medical.   As of April 23, 54 patients have been screened to assess if they are eligible to participate in the trial. Of these, 40 have